Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

September 01, 1982; Volume 22,Issue 2
  • You have access
    Enzyme regulatory site-directed drugs. MOdulation of thymidine triphosphate inhibition of thymidine kinase by 5'-amino-5'-deoxythymidine.
    P H Fischer and D Baxter
    Molecular Pharmacology September 1982, 22 (2) 231-234;
  • You have access
    N-oxidation of phentermine to N-hydroxyphentermine by a reconstituted cytochrome P-450 oxidase system from rabbit liver.
    J D Duncan and A K Cho
    Molecular Pharmacology September 1982, 22 (2) 235-238;
  • You have access
    Microsomal reduction of gentian violet. Evidence for cytochrome P-450-catalyzed free radical formation.
    W G Harrelson and R P Mason
    Molecular Pharmacology September 1982, 22 (2) 239-242;
  • You have access
    Characterization of solubilized serotonin (S2) receptors in rat brain.
    B Ilien, H Gorissen and P M Laduron
    Molecular Pharmacology September 1982, 22 (2) 243-249;
  • You have access
    Heterogeneity of adenosine A1 receptor binding in brain tissue.
    K M Murphy and S H Snyder
    Molecular Pharmacology September 1982, 22 (2) 250-257;
  • You have access
    Characterization of coexisting alpha 1- and beta 2-adrenergic receptors on a cloned muscle cell line, BC3H-1.
    R J Hughes, M R Boyle, R D Brown, P Taylor and P A Insel
    Molecular Pharmacology September 1982, 22 (2) 258-266;
  • You have access
    Magnesium regulation of the beta-receptor-adenylate cyclase complex. I. Effects of manganese on receptor binding and cyclase activation.
    S Y Cech and M E Maguire
    Molecular Pharmacology September 1982, 22 (2) 267-273;
  • You have access
    Magnesium regulation of the beta-receptor-adenylate cyclase complex. II. Sc3+ as a Mg2 antagonist.
    M E Maguire
    Molecular Pharmacology September 1982, 22 (2) 274-280;
  • You have access
    Further characterization of structural requirements for agonists at the striatal dopamine D-1 receptor. Studies with a series of monohydroxyaminotetralins on dopamine-sensitive adenylate cyclase and a comparison with dopamine receptor binding.
    M P Seiler and R Markstein
    Molecular Pharmacology September 1982, 22 (2) 281-289;
  • You have access
    Dopamine receptor of the porcine anterior pituitary gland. Evidence for two affinity states discriminated by both agonists and antagonists.
    A De Lean, B F Kilpatrick and M G Caron
    Molecular Pharmacology September 1982, 22 (2) 290-297;
  • You have access
    Dopamine receptor of the porcine anterior pituitary gland. Effects of N-ethylmaleimide and heat on ligand binding mimic the effects of guanine nucleotides.
    B F Kilpatrick, A De Lean and M G Caron
    Molecular Pharmacology September 1982, 22 (2) 298-303;
  • You have access
    Cholinergic muscarinic receptor in synaptosomal membranes. Heterogeneity of binding sites for L-[3H]quinuclidinyl benzilate.
    J S Aguilar, P J Salas and E De Robertis
    Molecular Pharmacology September 1982, 22 (2) 304-309;
  • You have access
    Muscarinic cholinergic receptor-mediated activation of phosphodiesterase.
    R B Meeker and T K Harden
    Molecular Pharmacology September 1982, 22 (2) 310-319;
  • You have access
    Guanine nucleotides and monovalent cations increase agonist affinity of prostaglandin E2 receptors in hamster adipocytes.
    R Grandt, K Aktories and K H Jakobs
    Molecular Pharmacology September 1982, 22 (2) 320-326;
  • You have access
    gamma-aminobutyric acid receptors modulate cation binding sites coupled to independent benzodiazepine, picrotoxin, and anion binding sites.
    R F Squires and E Saederup
    Molecular Pharmacology September 1982, 22 (2) 327-334;
  • You have access
    Thermodynamic changes associated with benzodiazepine and alkyl beta-carboline-3-carboxylate binding to rat brain homogenates.
    R L Kochman and J D Hirsch
    Molecular Pharmacology September 1982, 22 (2) 335-341;
  • You have access
    Thermodependence of guanine nucleotide-activated rat cardiac adenylate cyclase activity. Effect of cholera toxin pretreatment.
    P Chatelain, P Robberecht, M Waelbroeck, P De Neef, J Camus and J Christophe
    Molecular Pharmacology September 1982, 22 (2) 342-348;
  • You have access
    An analysis of binding at the opioid receptor based upon an agonist/antagonist two-state model.
    B V Cheney, R A Lahti, C Barsuhn and D D Gay
    Molecular Pharmacology September 1982, 22 (2) 349-359;
  • You have access
    The effects of exposure to unsaturated fatty acids on opiate receptors, prostaglandin E1 receptors, and adenylate cyclase activity of neuroblastoma x glioma hybrid cells.
    R McGee and J G Kenimer
    Molecular Pharmacology September 1982, 22 (2) 360-368;
  • You have access
    Modification of dose-response curves by effector blockade and uncompetitive antagonism.
    P Pennefather and D M Quastel
    Molecular Pharmacology September 1982, 22 (2) 369-380;
  • You have access
    Oxytocin action. Mechanisms for insulin-like activity in isolated rat adipocytes.
    K Hanif, H J Goren, M D Hollenberg and K Lederis
    Molecular Pharmacology September 1982, 22 (2) 381-388;
  • You have access
    Effects of acute and chronic morphine treatment of calmodulin activity of rat brain.
    R Nehmad, H Nadler and R Simantov
    Molecular Pharmacology September 1982, 22 (2) 389-394;
  • You have access
    Calmodulin inhibitors activate glycogen phosphorylase B to A conversion in C6 glioma cells.
    J A Norman and M Staehelin
    Molecular Pharmacology September 1982, 22 (2) 395-402;
  • You have access
    Hydrophobic interaction of the Ca2+-calmodulin complex with calmodulin antagonists. Naphthalenesulfonamide derivatives.
    T Tanaka, T Ohmura and H Hidaka
    Molecular Pharmacology September 1982, 22 (2) 403-407;
  • You have access
    Two types of calcium-dependent protein phosphorylations modulated by calmodulin antagonists. Naphthalenesulfonamide derivatives.
    T Tanaka, T Ohmura, T Yamakado and H Hidaka
    Molecular Pharmacology September 1982, 22 (2) 408-412;
  • You have access
    Effects of microtubular inhibitors on plasma membrane calmodulin-dependent Ca2+-transport ATPase.
    K Gietzen, A Wüthrich and H Bader
    Molecular Pharmacology September 1982, 22 (2) 413-420;
  • You have access
    Induction of tyrosine hydroxylase by glucocorticoids in mouse neuroblastoma cells. Enhancement of the induction by cyclic AMP.
    A W Tank and N Weiner
    Molecular Pharmacology September 1982, 22 (2) 421-430;
  • You have access
    Comparison of epileptogenic properties of unsubstituted and beta-alkyl-substituted gamma-butyrolactones.
    W E Klunk, D F Covey and J A Ferrendelli
    Molecular Pharmacology September 1982, 22 (2) 431-437;
  • You have access
    Anticonvulsant properties of alpha, gamma, and alpha, gamma-substituted gamma-butyrolactones.
    W E Klunk, D F Covey and J A Ferrendelli
    Molecular Pharmacology September 1982, 22 (2) 438-443;
  • You have access
    Structure-activity relationships of alkyl-substituted gamma-butyrolactones and succinimides.
    W E Klunk, D F Covey and J A Ferrendelli
    Molecular Pharmacology September 1982, 22 (2) 444-450;
  • You have access
    Kinetic determinants of benzo[a]pyrene metabolism to dihydrodiol epoxides by 3-methylcholanthrene-induced rat liver microsomes.
    G M Keller, C R Turner and C R Jefcoate
    Molecular Pharmacology September 1982, 22 (2) 451-458;
  • You have access
    Molecular orbital studies of epoxide stability of carcinogenic polycyclic aromatic hydrocarbon diol epoxides.
    S M Adams and L S Kaminsky
    Molecular Pharmacology September 1982, 22 (2) 459-464;
  • You have access
    The opposing effects of N-hydroxyamphetamine and N-hydroxyphentermine on the H2O2 generated by hepatic cytochrome P-450.
    A K Cho, M S Maynard, R M Matsumoto, B Lindeke, U Paulsen and G T Miwa
    Molecular Pharmacology September 1982, 22 (2) 465-470;
  • You have access
    Inhibition of microsomal oxidative drug metabolism by 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate, a new antineoplastic agent.
    E D Kharasch and R F Novak
    Molecular Pharmacology September 1982, 22 (2) 471-478;
  • You have access
    Prostaglandin synthetase-catalyzed activation of phenacetin metabolites to genotoxic products.
    B Andersson, M Nordenskjöld, A Rahimtula and P Moldéus
    Molecular Pharmacology September 1982, 22 (2) 479-485;
  • You have access
    Comparison of the in vivo and in vitro antileukemic activity of monosubstituted derivatives of 4'-(9-acridinylamino)methanesulfon-m-anisidide.
    B C Baguley and B F Cain
    Molecular Pharmacology September 1982, 22 (2) 486-492;
  • You have access
    Catecholamine-induced release of the folic acid analogue, methotrexate, from rat hepatocytes in suspension. An alpha-adrenergic phenomenon.
    D A Gewirtz, J K Randolph and I D Goldman
    Molecular Pharmacology September 1982, 22 (2) 493-499;
  • You have access
    A monoclonal antibody elicited to human platelet monoamine oxidase. Isolation and specificity for human monoamine oxidase B but not A.
    R M Denney, N T Patel, R R Fritz and C W Abell
    Molecular Pharmacology September 1982, 22 (2) 500-508;
  • You have access
    Rates of sulfation and glucuronidation of 7-hydroxycoumarin in periportal and pericentral regions of the liver lobule.
    J G Conway, F C Kauffman, S Ji and R G Thurman
    Molecular Pharmacology September 1982, 22 (2) 509-516;
  • You have access
    Effects of adenine nucleosides on RNA synthesis in adenovirus-infected cells. 9-beta-D-Arabinofuranosyladenine as a selective inhibitor of RNA polyadenylation.
    K M Rose, T B Leonard and T H Carter
    Molecular Pharmacology September 1982, 22 (2) 517-523;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 22, Issue 2
1 Sep 1982
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics